Considering this background, this study sought to 1) examine the efficacy of using TDM and neutralizing ADA detection to guide treatment decisions, 2) compare the remission rates in patients with and without neutralizing drug antibodies in 12 months, and 3) evaluate the prevalence of neutralizing drug antibodies in uveitis patients who have a suboptimal response to the initial dose of adalimumab. Here, ADA is linked to uveitis.